Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer

Author： Offersen Birgitte Vrou   Riisbro Rikke   Knoop Ann   Brünner Nils   Overgaard Jens   Group on behalf of the Danish Breast Cancer Cooperative   Committee Tumor Biology  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.46, Iss.6, 2007-01, pp. : 782-791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer

By Fredstorp-Lidebring M.   Bendahl P.-O.   Brunner N.   Casslen B.   Hogberg T.   Langstrom-Einarsson E.   Willen R.   Ferno M.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2339-2348

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

By Kute T.E.  

Breast Cancer Research and Treatment, Vol. 47, Iss. 1, 1998-01 ,pp. : 9-16

Springer Publishing Company

Access to resources Recommend Favorite

Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer

By Wang Bin  

The Chinese-German Journal of Clinical Oncology, Vol. 7, Iss. 6, 2008-06 ,pp. : 339-343

Springer Publishing Company

Access to resources Recommend Favorite

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

By          

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 637-645

Spandidos Publications

Access to resources Recommend Favorite